Literature DB >> 19889758

Mouse-specific residues of claudin-1 limit hepatitis C virus genotype 2a infection in a human hepatocyte cell line.

Sibylle Haid1, Marc P Windisch, Ralf Bartenschlager, Thomas Pietschmann.   

Abstract

Recently, claudin-1 (CLDN1) was identified as a host protein essential for hepatitis C virus (HCV) infection. To evaluate CLDN1 function during virus entry, we searched for hepatocyte cell lines permissive for HCV RNA replication but with limiting endogenous CLDN1 expression, thus permitting receptor complementation assays. These criteria were met by the human hepatoblastoma cell line HuH6, which (i) displays low endogenous CLDN1 levels, (ii) efficiently replicates HCV RNA, and (iii) produces HCV particles with properties similar to those of particles generated in Huh-7.5 cells. Importantly, naïve cells are resistant to HCV genotype 2a infection unless CLDN1 is expressed. Interestingly, complementation of HCV entry by human, rat, or hamster CLDN1 was highly efficient, while mouse CLDN1 (mCLDN1) supported HCV genotype 2a infection with only moderate efficiency. These differences were observed irrespective of whether cells were infected with HCV pseudoparticles (HCVpp) or cell culture-derived HCV (HCVcc). Comparatively low entry function of mCLDN1 was observed in HuH6 but not 293T cells, suggesting that species-specific usage of CLDN1 is cell type dependent. Moreover, it was linked to three mouse-specific residues in the second extracellular loop (L152, I155) and the fourth transmembrane helix (V180) of the protein. These determinants could modulate the exposure or affinity of a putative viral binding site on CLDN1 or prevent optimal interaction of CLDN1 with other human cofactors, thus precluding highly efficient infection. HuH6 cells represent a valuable model for analysis of the complete HCV replication cycle in vitro and in particular for analysis of CLDN1 function in HCV cell entry.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19889758      PMCID: PMC2798385          DOI: 10.1128/JVI.01504-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  65 in total

1.  Use of VSV-G pseudotyped retroviral vectors to target murine osteoprogenitor cells.

Authors:  I Kalajzic; M L Stover; P Liu; Z Kalajzic; D W Rowe; A C Lichtler
Journal:  Virology       Date:  2001-05-25       Impact factor: 3.616

2.  Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor.

Authors:  V Agnello; G Abel; M Elfahal; G B Knight; Q X Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

3.  Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2.

Authors:  Ania Owsianka; Reginald F Clayton; Lawrence D Loomis-Price; Jane A McKeating; Arvind H Patel
Journal:  J Gen Virol       Date:  2001-08       Impact factor: 3.891

4.  Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor.

Authors:  Birke Bartosch; Alessandra Vitelli; Christelle Granier; Caroline Goujon; Jean Dubuisson; Simona Pascale; Elisa Scarselli; Riccardo Cortese; Alfredo Nicosia; François-Loïc Cosset
Journal:  J Biol Chem       Date:  2003-08-11       Impact factor: 5.157

5.  Characterization of low- and very-low-density hepatitis C virus RNA-containing particles.

Authors:  P André; F Komurian-Pradel; S Deforges; M Perret; J L Berland; M Sodoyer; S Pol; C Bréchot; G Paranhos-Baccalà; V Lotteau
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

6.  Analysis of antigenicity and topology of E2 glycoprotein present on recombinant hepatitis C virus-like particles.

Authors:  Reginald F Clayton; Ania Owsianka; Jim Aitken; Susan Graham; David Bhella; Arvind H Patel
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

7.  Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor.

Authors:  David M Owen; Hua Huang; Jin Ye; Michael Gale
Journal:  Virology       Date:  2009-09-13       Impact factor: 3.616

8.  Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants.

Authors:  Maria Teresa Catanese; Helenia Ansuini; Rita Graziani; Thierry Huby; Martine Moreau; Jonathan K Ball; Giacomo Paonessa; Charles M Rice; Riccardo Cortese; Alessandra Vitelli; Alfredo Nicosia
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

9.  The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus.

Authors:  Elisa Scarselli; Helenia Ansuini; Raffaele Cerino; Rosa Maria Roccasecca; Stefano Acali; Gessica Filocamo; Cinzia Traboni; Alfredo Nicosia; Riccardo Cortese; Alessandra Vitelli
Journal:  EMBO J       Date:  2002-10-01       Impact factor: 11.598

10.  Low pH-dependent hepatitis C virus membrane fusion depends on E2 integrity, target lipid composition, and density of virus particles.

Authors:  Sibylle Haid; Thomas Pietschmann; Eve-Isabelle Pécheur
Journal:  J Biol Chem       Date:  2009-05-01       Impact factor: 5.157

View more
  31 in total

Review 1.  Adaptive immunity to the hepatitis C virus.

Authors:  Christopher M Walker
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

2.  Replication of subgenomic hepatitis C virus replicons in mouse fibroblasts is facilitated by deletion of interferon regulatory factor 3 and expression of liver-specific microRNA 122.

Authors:  Liang-Tzung Lin; Ryan S Noyce; Tram N Q Pham; Joyce A Wilson; Gary R Sisson; Thomas I Michalak; Karen L Mossman; Christopher D Richardson
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

3.  Selection of a hepatitis C virus with altered entry factor requirements reveals a genetic interaction between the E1 glycoprotein and claudins.

Authors:  Sharon E Hopcraft; Matthew J Evans
Journal:  Hepatology       Date:  2015-05-12       Impact factor: 17.425

4.  Arginine-rhamnosylation as new strategy to activate translation elongation factor P.

Authors:  Jürgen Lassak; Eva C Keilhauer; Maximilian Fürst; Kristin Wuichet; Julia Gödeke; Agata L Starosta; Jhong-Min Chen; Lotte Søgaard-Andersen; Jürgen Rohr; Daniel N Wilson; Susanne Häussler; Matthias Mann; Kirsten Jung
Journal:  Nat Chem Biol       Date:  2015-02-16       Impact factor: 15.040

5.  Establishment of a novel permissive cell line for the propagation of hepatitis C virus by expression of microRNA miR122.

Authors:  Hiroto Kambara; Takasuke Fukuhara; Mai Shiokawa; Chikako Ono; Yuri Ohara; Wataru Kamitani; Yoshiharu Matsuura
Journal:  J Virol       Date:  2011-11-23       Impact factor: 5.103

6.  HepG2 cells expressing microRNA miR-122 support the entire hepatitis C virus life cycle.

Authors:  Christopher M Narbus; Benjamin Israelow; Marion Sourisseau; Maria L Michta; Sharon E Hopcraft; Gusti M Zeiner; Matthew J Evans
Journal:  J Virol       Date:  2011-09-14       Impact factor: 5.103

7.  FAK Inhibition Decreases Hepatoblastoma Survival Both In Vitro and In Vivo.

Authors:  Lauren A Gillory; Jerry E Stewart; Michael L Megison; Hugh C Nabers; Elizabeth Mroczek-Musulman; Elizabeth A Beierle
Journal:  Transl Oncol       Date:  2013-04-01       Impact factor: 4.243

8.  Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies.

Authors:  Isabel Fofana; Samira Fafi-Kremer; Patric Carolla; Catherine Fauvelle; Muhammad Nauman Zahid; Marine Turek; Laura Heydmann; Karine Cury; Juliette Hayer; Christophe Combet; François-Loïc Cosset; Thomas Pietschmann; Marie-Sophie Hiet; Ralf Bartenschlager; François Habersetzer; Michel Doffoël; Zhen-Yong Keck; Steven K H Foung; Mirjam B Zeisel; Françoise Stoll-Keller; Thomas F Baumert
Journal:  Gastroenterology       Date:  2012-04-10       Impact factor: 22.682

9.  Adaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors.

Authors:  Julia Bitzegeio; Dorothea Bankwitz; Kathrin Hueging; Sibylle Haid; Christiane Brohm; Mirjam B Zeisel; Eva Herrmann; Marcus Iken; Michael Ott; Thomas F Baumert; Thomas Pietschmann
Journal:  PLoS Pathog       Date:  2010-07-01       Impact factor: 6.823

10.  Recycling of peptidyl-tRNAs by peptidyl-tRNA hydrolase counteracts azithromycin-mediated effects on Pseudomonas aeruginosa.

Authors:  Julia Gödeke; Christian Pustelny; Susanne Häussler
Journal:  Antimicrob Agents Chemother       Date:  2013-01-14       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.